Table 4.
Metabolic characteristics of child survivors of leukemia and lymphoma according to treatment at 6-months
| Treatment | ||||
|---|---|---|---|---|
| Chemotherapya n = 32 | Chemotherapy plus radiotherapy n =17 | |||
| Variables | Normal | Overweigth/Obese | Normal | Overweigth/Obese |
| n: number (%) | 18 | 14 (40) | 9 | 8 (47) |
| Sex: M | 13 | 11 | 6 | 7 |
| Current age (Y) | 12.5 (8.0, 17.1) | 11.6 (8.0, 17.1) | 14.0 (8.4, 17.0) | 13.0 (8.1, 18.0) |
| Age at cancer diagnosis (Y) | 6.0 (2, 13) | 4.0 (2, 12) | 6.0 (0.08, 12) | 70 (1.0, 11.1) |
| Time since completion of therapy (Y) | 4.0 (2.1, 5.0) | 4.0 (2.1, 5.0) | 3.1 (3.0, 5.0) | 4.0 (2.0, 5.0) |
| Δ Body weight (kg) (6 mo - first assessement) | 1.6 (−2.5, 5.3) | 2.0 (−1.2, 5.1) | ||
| Δ Height (cm) (6 mo - first assessment) | 2.6 (1.7, 6.0) | 1.0 (0.2, 3.5)* | ||
| Diagnosis : ALL/Lymphoma | 11/7 | 9/5 | 3/6 | 2/6 |
| Pubertal stage | ||||
| 1 | 8 | 9 | 3 | 2 |
| ≥ 2 | 10 | 5 | 6 | 6 |
| MS Components | ||||
| WC (pc) | 25 (10, 50) | 90 (35, 100)* | 30 (10, 50) | 83 (50, 90)** |
| SBP (pc) | 15.5 (0, 55) | 64 (2, 95)* | 13 (1, 38) | 21 (3, 65) |
| DBP (pc) | 54 (22, 92) | 87 (13, 99)* | 53 (38, 79) | 71 (39, 85) |
| Triglicerydes (mg/dL) | 80 (28, 191) | 124 (66, 264)* | 91 (28, 259) | 105 (56, 218) |
| HDL-C (mg/dL) | 47.3 (24.6, 79.5) | 38.5 (21.7, 67.6)* | 46 (32, 56) | 37 (20, 60) |
| Glucose (mg/dL) | 93 (76.6, 102) | 97.5 (83.5, 115) | 88.5 (76.6, 100.6) | 92.6 (82.7, 101.2) |
| Others metabolic variables | ||||
| Insulin (μU/mL) | 25 (8.3, 35.4) | 33.4 (22.8, 64)* | 14.9 (3.4, 43.9) | 28.9 (16.9, 52.3) |
| HOMA-IR | 4.8 (1.7, 7.0) | 7.8 (5.2, 15.4)* | 3.4 (0.68, 10.9) | 6.6 (4.0, 11.4) |
| Adiponectin (μg/mL) | 21.9 (7.7, 42.1) | 20.2 (6.6, 57.3) | 20.9 (11.6, 28.9) | 15.3 (0.64, 33.0) |
| Adiponectin per Kg fat (μg/mL/kg) | 1.7 (0.45, 14.3) | 1.0 (0.27, 4.2) | 1.9 (0.62, 4.2) | 0.78 (0.06, 6.6) |
| Leptin ((μg/mL) | 5.2 (1.8, 30.9) | 21 (9.4, 40.7)* | 6.2 (1.6, 25.1) | 9.5 (3.6, 27.6) |
| Leptin per Kg fat (μg/mL/kg) | 0.63 (0.13, 2.6) | 1.1 (0.30, 4.4)* | 0.39 (0.11, 4.8) | 0.67 (0.13, 4.2) |
| Leptin to Adiponectin ratio | 0.26 (0.05, 1.1) | 1.2 (0.81, 3.5)* | 0.34 (0.11, 1.2) | 0.93 (0.11, 10.4) |
| Body Fat (%) | 22 (11.2, 35.7) | 39.8 (33.4, 49.3)* | 23 (10.9, 43.4) | 30.7 (18.7, 37.7) |
| VCAM (ng/mL) | 801 (503, 2045) | 818 (514, 1522) | 617 (377, 1166) | 727 (394, 1178) |
| ICAM (ng/mL) | 404 (234, 753) | 440 (200. 1124) | 571 (184, 966) | 411 (307, 1037) |
| MS | ||||
| Yes/No | 0/18 | 7/14 | 0/9 | 3/5 |
Values are median (min, max); Abbreviations: MS Metabolic syndrome, HOMA-IR Homeostatic Model Assessment of Insulin Resistance, VCAM Vascular cell adhesion molecule, ICAM Intercellular adhesion molecule. Data compared Mann–Whitney U-test. Categorized Data were analyzed using Fisher’s Test. aThree children of Chemotherapy group were excluded, because they were underweight; * p value < 0.05; **p value = 0.065